<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31432691</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7-8</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Neurofilaments in pre-symptomatic ALS and the impact of genotype.</ArticleTitle><Pagination><StartPage>538</StartPage><EndPage>548</EndPage><MedlinePgn>538-548</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1646769</ELocationID><Abstract><AbstractText><i>Objective</i>. To evaluate serum and cerebrospinal fluid (CSF) levels of phosphorylated neurofilament heavy (pNfH), and to compare these to levels of neurofilament light (NfL), as biomarkers of pre-symptomatic ALS. <i>Design</i>. The study population includes 34 controls, 79 individuals at-risk for ALS, 22 ALS patients, and 14 phenoconverters. At-risk individuals are enrolled through <i>Pre-Symptomatic Familial ALS</i> (<i>Pre-fALS</i>), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation, but who demonstrate no clinical evidence of disease at the time of enrollment. pNfH and NfL in serum and CSF were quantified using established enzyme-linked immunosorbent assays. <i>Results</i>. There is a longitudinal increase in serum pNfH in advance of the emergence of clinically manifest ALS. A similar pattern is observed for NfL, but with the absolute levels also frequently exceeding a normative threshold. Although CSF data are more sparse, similar patterns are observed for both neurofilaments, with absolute levels exceeding a normative threshold prior to phenoconversion. In serum, these changes are observed in the 6-12 months prior to disease among <i>SOD1</i> A4V mutation carriers, and as far back as 2 and 3.5 years, respectively, in individuals with a <i>FUS</i> c.521del6 mutation and a <i>C9ORF72</i> hexanucleotide repeat expansion. <i>Conclusions</i>. Serum and CSF pNfH increase prior to phenoconversion. In CSF, the temporal course of these changes is similar to NfL. In serum, however, pNfH is less sensitive to pre-symptomatic disease than NfL. The duration of pre-symptomatic disease, as defined by changes in neurofilaments, may vary depending on underlying genotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami , Miami , FL , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami , Miami , FL , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuroscience Center, Blizard, Institute of Cell and Molecular Medicine, Barts &amp; the London School of Medicine &amp; Dentistry , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeromin</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Iron Horse Diagnostics , Phoenix , AZ , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Iron Horse Diagnostics , Phoenix , AZ , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University , Ume&#xe5; , Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Center, Blizard, Institute of Cell and Molecular Medicine, Barts &amp; the London School of Medicine &amp; Dentistry , London , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MALASPINA/APR13/817-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31432691</ArticleId><ArticleId IdType="mid">NIHMS1536606</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nature medicine 2019;25:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Poole T, O&#x2019;Connor A, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer&#x2019;s disease. Alzheimers Res Ther 2019;11:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383280</ArticleId><ArticleId IdType="pubmed">30786919</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology 2017;89:2167&#x2013;2175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696646</ArticleId><ArticleId IdType="pubmed">29070659</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostgaard N, Roos P, Portelius E, et al. CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. Neurology 2018;90:e157&#x2013;e163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772154</ArticleId><ArticleId IdType="pubmed">29237796</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Annals of neurology 2014;75:116&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of clinical and translational neurology 2016;3:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington&#x2019;s disease: a retrospective cohort analysis. Lancet Neurol 2017;16:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507767</ArticleId><ArticleId IdType="pubmed">28601473</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinther-Jensen T, Bornsen L, Budtz-Jorgensen E, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurology(R) neuroimmunology &amp; neuroinflammation 2016;3:e287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042104</ArticleId><ArticleId IdType="pubmed">27734023</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild E, Tabrizi S. Premanifest and early Huntington&#x2019;s disease In: Bates G, Tabrizi S, Jones L, eds. Huntington&#x2019;s Disease. Pages 86&#x2013;106. New York: Oxford University Press, 2014.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of pre-symptomatic ALS and phenoconversion. Annals of neurology 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 2015;86:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Lu CH, Cho Y, et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J Neurochem 2018;146:631&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175430</ArticleId><ArticleId IdType="pubmed">29959860</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Pre-Symptomatic Studies in ALS: Rationale, Challenges and Approach. Neurology 2012;79:1732&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner M, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler and Frontotemporal Degeneration 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiutori R, Aarum J, Zubiri I, et al. The proteome of neurofilament-containing protein aggregates in blood. Biochem Biophys Rep 2018;14:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986704</ArticleId><ArticleId IdType="pubmed">29872749</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Polak M, Kaplan S, Glass J. Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible? Journal of the neurological sciences 2006;251:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17005203</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Polak M, Feng R. Predicting the risk of disease in familial amyotrophic lateral sclerosis. American Neurological Association 133rd Annual Meeting Salt Lake City2008.</Citation></Reference><Reference><Citation>Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010;153B:397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048807</ArticleId><ArticleId IdType="pubmed">19548255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild EJ, Petzold A, Keir G, Tabrizi SJ. Plasma neurofilament heavy chain levels in Huntington&#x2019;s disease. Neurosci Lett 2007;417:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363167</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of clinical and translational neurology 2018;5:583&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of neurology 2016;79:152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>